News | July 06, 2022
Wacker to expand mRNA-based actives capacity at Halle, Germany
Company is investing more than €100 million in the expansion of the Halle site
Company is investing more than €100 million in the expansion of the Halle site
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Subscribe To Our Newsletter & Stay Updated
